Article

Neuroanatomic Profile of Polyglutamine Immunoreactivity inHuntington Disease Brains

Division of Neuropathology, Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9073, USA.
Journal of Neuropathology and Experimental Neurology (Impact Factor: 4.37). 04/2009; 68(3):250-61. DOI: 10.1097/NEN.0b013e318198d320
Source: PubMed

ABSTRACT A pathologic hallmark of Huntington disease (HD) is the presence of intraneuronal aggregates of polyglutamine-containing huntingtin protein fragments. Monoclonal antibody 1C2 is a commercial antibody to normal human TATA-binding protein that detects long stretches of glutamine residues. Using 1C2 as a surrogate marker formutant huntingtin protein, we immunostained 19 HD cases, 10 normal controls, and 10 cases of frontotemporal degeneration with ubiquitinated inclusions as diseased controls. In the HD cases, there was consistent 1C2 immunoreactivity in the neocortex, striatum, hippocampus, lateral geniculate body, basis pontis, medullary reticular formation, and cerebellar dentate nucleus. The normal and diseased controls demonstrated 1C2 immunoreactivity only in the substantia nigra, locus coeruleus, and pituitary gland. Staining of 5 HD cases and 5 normal controls revealed a less consistent and less diagnostically useful morphologic immunoreactivity profile. These results indicate that widespread 1C2 immunoreactivity is present in diverse central nervous system areas in HD, and that in the appropriate setting, 1C2 staining can be a useful tool in the postmortem diagnosis of HD when neuromelanin-containing neuronal populations are avoided.

2 Followers
 · 
113 Views
    • "The inclusions are present prior to symptomatic development of the disease in the human brain and found throughout the cortex, but less frequently in the striatum [92] [93] [94] [95] [96]. Within the cortex, the cells tend to display combinations of nuclear and cytoplasmic as well as neuropil aggregations [95] with the highest levels of intranuclear inclusions found in juvenile cases which tend to have relatively very high CAG repeat Fig. 2. Photomicrographs illustrating the pyramidal neurons in layer III in the primary motor cortex (A–C) and anterior cingulate cortex (D–F) of normal (A, D) and Huntington's disease cases (B, C; E, F). The images illustrate cases with " mainly motor " (B, E), and " mainly mood " (C, F) symptom profiles. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We review recent investigations regarding the relationship between selective neurodegeneration in the human brain and the variability in symptom profiles in Huntington's disease. Huntington's disease is a genetic neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the Huntingtin gene on chromosome 4, encoding a protein called huntingtin. The huntingtin protein is expressed ubiquitously in somatic tissue, however, the major pathology affects the brain with profound degeneration in the striatum and the cerebral cortex. Despite the disease being caused by a single gene, there is a major variability in the neuropathology, as well as major heterogeneity in the symptom profiles observed in Huntington's disease patients. The symptoms may vary throughout the disease course and present as varying degrees of movement disorder, cognitive decline, and mood and behavioral changes. To determine whether there is an anatomical basis underlying symptom variation, recent studies on the post-mortem human brain have shown a relationship between the variable degeneration in the forebrain and the variable symptom profile. In this review, we will summarize the progress relating cell loss in the striatum and cerebral cortex to symptom profile in Huntington's disease.
  • [Show abstract] [Hide abstract]
    ABSTRACT: New and efficient luminaires have been designed for compact, twin tube-type fluorescent lamps. One important example of these new fixture applications is the 1×1 ft luminaire with three 18 W high lumen twin tube fluorescent lamps. Performance comparisons with this luminaire type have been made using different 18 W lamps operating on preheat and rapid start-type ballasts. The preheat (switch start) measurements were made at 240 V and 50 Hz using single lamp reactor type ballasts, and the rapid start measurements were made at 120 V and 60 Hz using three-lamp electromagnetic and electronic ballasts. In addition, comparisons are made against an older technology 150 W incandescent downlight fixture with approximately the same light output level indicating the substantial improvement in system photometric performance for these new compact fluorescent light sources
    IEEE Transactions on Industry Applications 06/1991; DOI:10.1109/28.81827 · 2.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurodegenerative diseases are characterized by a number of features including the formation of inclusions, early synaptic degeneration and the selective loss of neurons. Molecules serving as links between these shared features have yet to be identified. Identifying candidates within the diseased microenvironment will open up novel avenues for therapeutic intervention. The transcription factor Elk-1 resides within multiple brain areas both in nuclear and extranuclear neuronal compartments. Interestingly, its de novo expression within a single dendrite initiates neuronal death. Given this novel regionalized function, we assessed whether extranuclear Elk-1 and/or phospho-Elk-1 (pElk-1) protein might be associated with a spectrum of human neurodegenerative disease cases including Lewy body Disease (e.g. Parkinson's), Alzheimer's disease, and Huntington's Disease. We first determined the importance of Elk-1 post-translational modifications on its ability to initiate regionalized cell death. We next screened human cases from three major neurodegenerative diseases to look for remarkable levels of Elk-1 and/or pElk-1 protein as well as their association with inclusions characteristic of these diseases. We compared our findings to age-matched control cases. We find that the ability of Elk-1 to initiate regionalized neuronal death depends on a specific phosphosite, T417. Furthermore, we find that T417(+) Elk-1 uniquely associates with several types of inclusions present in cases of human Lewy body Disease, Alzheimer's disease, and Huntington's Disease. These results suggest a molecular link between the presence of inclusions and neuronal loss that is shared across a spectrum of neurodegenerative disease.
    PLoS ONE 02/2010; 5(2):e9002. DOI:10.1371/journal.pone.0009002 · 3.53 Impact Factor
Show more